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Immunity, immunosuppression and 
post-transplant malignancy
A relationship between the use of general immuno-
suppressive drugs to prevent allograft rejection and the 
development of cancer after organ transplantation has 
been recognised for decades. Th e scientiﬁ c transplant 
community has developed a growing concern about 
cancer, since post-transplant malignancy has emerged as 
a leading cause of morbidity and mortality, especially in 
patients who have a high or long-term exposure to 
immunosuppression [1,2]. Th ere are diﬀ erent explana-
tions for why post-transplant malignancy occurs more 
frequently in this pharmacologically immunosuppressed 
population, including enhancement of tumour invasive 
properties [3] and reduction in DNA repair mechanisms 
[4]. However, the most discussed mechanism is the 
seemingly obvious eﬀ ect of suppressing the ability of 
immune cells to detect and eliminate cancer as it 
develops (immune surveillance). Although one might be 
intuitive to hypothesise that all immunosuppressive 
drugs will have the same suppressive eﬀ ect against 
tumour immunity, recent research suggests that this may 
not be the case. New basic questions have therefore been 
raised, including the following: how do mammalian target 
of rapamycin (mTOR) inhibitors aﬀ ect the develop ment 
of speciﬁ c immune cells that are most critical to produce 
an eﬀ ective anti-tumour immune response? Do the 
various immunosuppressive drugs aﬀ ect these cells 
diﬀ erently? Is it possible to enhance an immune response 
towards a tumour, while at the same time inhibiting 
immunity towards a transplanted allograft? Since the 
most common tumours that develop in transplant recipi-
ents are virally associated [5], how do mTOR inhibitors 
inﬂ uence speciﬁ c viral infections in these patients?
Certainly intriguing is the fact that speciﬁ c immune 
responses formed simultaneously against an allograft and 
a (immunogenic) tumour may be diﬀ erent in nature, and 
are likely to be altered signiﬁ cantly by various immuno-
suppressive substances, depending on the answers to the 
questions posed above. Th e present review focuses on 
new evidence that the mTOR pathway is uniquely 
positioned to aﬀ ect the diﬀ erential development of 
lymphocyte subpopulations, as well as the maturation of 
antigen-presenting cell (APC) populations, all of which 
are critical in the formation of immune responses 
towards organ transplants and tumours. Interestingly, 
some of the aﬀ ected immune cell types sway immunity 
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towards suppressive regulation, and others enhance 
eﬀ ector cell capabilities. With regard to organ trans plan-
tation recipients, the ideal overall eﬀ ect sought thera-
peutically is complex, and demanding, in that it is 
desirable to minimise the immune response against the 
allograft, while at the same time enhancing immunity 
against tumours (and infectious microorganisms). 
Although this suggestion appears to be mutually exclu-
sive, there are reasons to believe that the development of 
such a diametrically opposing response to an organ 
transplant and a tumour or microorganism may be 
possible. In this article the eﬀ ects of mTOR inhibitors on 
diﬀ erent cellular components of the immune system are 
reviewed. Th e aim is to put forward the latest information 
regarding the eﬀ ects of mTOR inhibition on immunity in 
the context of reducing the complex problem of post-
transplant malignancy in transplant recipients.
Immunosuppressive and immunomodulatory 
eff ects of mTOR inhibitors
Inhibitors of mTOR have been used for more than a 
decade as immunosuppressive agents to prevent organ 
transplant rejection. Early mechanistic studies on rapa-
mycin pointed towards a rather simple explanation for 
the immunosuppressive eﬀ ect, in that the mTOR pathway 
was found to be essential for the cell proliferation signal 
(often referred to as signal 3) triggered by IL-2, thus 
preventing the expansion of donor-speciﬁ c T cells 
activated through the T-cell receptor [6]. Th is immuno-
suppressive eﬀ ect contrasts in general with calcineurin 
inhibitors (CNIs), which act by preventing the initial acti-
vation (signal 1) of T cells [7]. While our overall mecha-
nistic understanding of the basic suppressive activity of 
CNIs is still generally accepted, new data suggest that the 
suppressive eﬀ ect of mTOR inhibition on immune cells is 
very complex and probably does not rest primarily on 
inhibition of T-cell proliferation.
Recent mechanistic investigations indicate that mTOR 
plays a central role in the diﬀ erentiation of T-cell subsets, 
and also controls aspects of B-cell and APC development. 
In fact, mTOR is a critical regulator of the immune res-
ponse because it acts as a central node for sensing nutrient 
availability, cytokine/growth factor signalling and co-
stimulatory factors (Figure 1). Indeed, mTOR is in a unique 
intracellular signalling position to integrate all of these 
factors so cells can eﬀ ectively and properly balance cues 
from the ever-changing microenvironment, such as those 
induced by microbiological (for example, bacterial, viral) 
or allo geneic (for example, organ transplant, tumour) 
challenges.
Role of mTOR in immune cell development – T cells
T cells are critically involved at nearly all levels of any 
immune response. While the primary eﬀ ect of mTOR 
inhibition on T cells was initially attributed to blockage 
of IL-2 proliferation-inducing signalling, hints that this is 
not the only eﬀ ect have become evident. One clue was 
that the initial ﬁ nding that rapamycin treatment induces 
T-cell anergy (lack of responsiveness) through inhibition 
of proliferation [8,9] was later found to be independent of 
this anti-proliferative eﬀ ect, and rather to be due to a 
direct inhibitory eﬀ ect on mTOR itself [10]. Subsequent 
investigations into the link of mTOR to T-cell metabo-
lism, and to transcription factors that are now recognised 
to control T-cell subset diﬀ erentiation, opened new views 
towards mTOR inhibitor eﬀ ects on the immune response.
Regarding metabolism, mTOR’s central role comes 
directly into play because activated lymphocytes pri-
marily use glycolysis for energy due to their need to 
produce proteins, nucleotides and lipids that are essential 
for the generation of key biosynthetic substrates [11,12]; 
the shifting from mitochondrial respiration to glycolysis 
(referred to as the Warburg eﬀ ect) is similar to that which 
occurs in cancer cells. Interestingly, mTOR as a regulator 
of metabolism provides links to lymphocyte activation in 
this context. One example is that T-cell co-stimulation 
via CD28 triggers the activation of signalling molecules 
upstream of mTOR that promote expression of necessary 
membrane glucose transporters. In general, one can state 
that inhibition of cell metabolism through mTOR leads to 
inhibition of T-cell-mediated immunity. Th e importance 
of this idea cannot be overstressed since it has been 
shown, for instance, that T-cell anergy is due at least in 
part to decreased mTOR activation [13]; if mTOR is 
resistant to reactivation in an anergic state, then the 
required metabolic machinery is not going to be available 
and the cell will remain anergic to otherwise stimulatory 
signals. Indeed, substances such as metformin and 
AICAR, which mimic energy depletion and activate 
Figure 1. Integration of various signals through mammalian 
target of rapamycin in lymphocytes. PTEN, phosphatase and 
tensin homolog; Rheb, Ras homolog enriched in brain; TSC, tuberous 
sclerosis.
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AMPK (an inhibitor of mTOR), promote T-cell anergy 
[13-15]. Cell metabolism, mTOR and the immune res-
ponse currently constitute an intense area of basic 
research that has substantial therapeutic potential and 
implications.
Th e diﬀ erentiation of CD4 and CD8 T-cell populations 
has a major impact on the development of any immune 
response to allogeneic transplants or tumour entities. 
Recent data demonstrate an important role for mTOR in 
determining the T-cell diﬀ erentiation pattern (Figure 2). 
To understand this role better, ﬁ rst it is necessary to 
recognise that mTOR is part of two large complexes, 
referred to as mTOR complex  1 (mTORC1) and mTOR 
complex  2 (mTORC2), where mTORC1 is directly inhi-
bited by rapamycin while mTORC2 is only indirectly and 
partially inhibited with long-term exposure to the drug. 
Second, it is helpful to know that diﬀ erentiation of Th 1, 
Th 2 and Th 17 T-helper cell subsets is regulated by the 
lineage-speciﬁ c transcription factors T-bet, GATA-3 and 
RORγt, respectively. Considering this background infor-
ma tion, recent experimental models suggest that block ing 
of mTORC1 with rapamycin, or by knocking out essential 
components of the mTORC1, a Th 2 polarised T-cell 
dominance develops; whereas knocking out mTORC2 
polarises the T-helper immune response towards Th 1 
and Th 17 cell development [16]. Most interestingly, 
blocking both mTOR complexes leads to the generation 
of a Foxp3+ T-regulatory (Treg) cell expansion. Moreover, 
these Treg cells are resistant to apoptosis [17]. Indeed, 
Treg cells appear in general to require less mTOR activity, 
which is consistent with the reduced metabolic demands 
for these cells compared with eﬀ ector T cells [18]. 
Interestingly, although Treg cells depend on IL-2 for 
proliferation, IL-2 stimulation results in high levels of 
STAT5 phosphorylation, rather than activation of mTOR 
[19], suggesting that diﬀ erent T-cell subpopulations 
depend on alternate signalling pathways for expansion 
and survival. In terms of thera peutic application of mTOR 
inhibitors, research suggests that the diﬀ erential eﬀ ects 
summarised above depend substantially on the dose, 
duration and timing of the drug application [20-22], 
indicating that more is to be learnt about how best to apply 
mTOR inhibitors to suit the clinical purpose intended.
Some of the same eﬀ ects apply to CD8+ cells regarding 
mTOR dependence. For instance, activation of CD8+ cells 
also primarily depends on glycolysis [23], and diﬀ er en tia-
tion of eﬀ ector CD8+ cells requires mTORC1-dependent 
T-bet expression [24]. Most critically, mTOR is involved 
in the transition of eﬀ ector to memory CD8+ T cells 
(Figure 2), and this appears to rely on conversion of T-bet 
to eomesodermin transcription factor expression [24-26]; 
blocking mTOR with rapamycin has this exact eﬀ ect, and 
therefore promotes the development and sustenance of 
memory T cells that transition eﬃ  ciently into eﬀ ector 
cells highly capable of producing immune responses to, 
for instance, tumours [24]. Similar to Treg cells, memory 
CD8+ T cells depend on mitochondrial oxidative phos-
phory lation for energy (rather than glycolysis) and are 
driven by STAT5 signalling. One perplexing question is 
therefore whether mTOR inhibition increases immunity 
to viruses, bacteria and tumours, while at the same time 
protects organ transplants from rejection.
Recent data suggest that rapamycin treatment aug-
ments CD8+ T-cell memory responses towards viruses. 
Th is eﬀ ect has been demonstrated by impressive boosting 
of vaccination responses both in mice [27,28] and in non-
human primate studies [29]; in the nonhuman primate 
experiments, immunosuppressive doses of sirolimus 
promoted CD8+ T-cell memory towards vaccinia virus, 
while CNI use did not. Indeed, it is ironic that an 
immunosuppressive agent is being considered for 
boosting vaccination responses in humans. Another 
inter est ing aspect of this research is that viral infections 
(for example, human papillomavirus, hepatitis B/C, 
Epstein–Barr virus, human herpesvirus 8) are associated 
with the most common post-transplant malignancies, 
suggesting that a boost in immunity to these viruses 
could aﬀ ect cancer development. Moreover, several 
recent experimental studies indicate that rapamycin 
adminis tration directly enhances memory T-cell forma-
tion against tumours [22,24]. Th is is an observation we 
have also been able to conﬁ rm in the laboratory [30], and 
Figure 2. Selective mammalian target of rapamycin complex 
1/2 blockade leads to diff erential development of T-cell 
subpopulations. Selective blockade of mammalian target of 
rapamycin complex 1 (mTORC1) and mammalian target of rapamycin 
complex 2 (mTORC2) leads to diff erential development of T-cell 
subpopulations. Tregs, T-regulatory cells.
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we can add that CNIs do not support memory develop-
ment in our models. Th e boosting of T-cell memory with 
mTOR inhi bition has substantial therapeutic implications 
regarding the problems of viral infection and post-
transplant malignancy in organ transplant recipients.
Th is leads to the question raised earlier of whether an 
immune response can be promoted in one foreign entity 
(for example, virus, bacteria or tumour cell) and yet 
inhibited by another (an organ transplant). An interesting 
experimental study from Ferrer and colleagues demon-
strates that rapamycin-treated mice have protection 
against rejection of an OVA-expressing skin allograft, 
while at the same time showing a heightened CD8+ T-cell 
response against the same OVA epitope expressed by 
bacteria (Listeria monocytogenes) [31]. Th is is a critical 
observation, since it opens the possibility that mTOR 
inhibitors can enhance immunity to infectious agents 
without at the same time promoting the immune reaction 
against an organ allo graft. In fact, it can be argued that 
enhancement of CD4+ Treg cell and CD8+ T suppressor 
cell [32] responses towards allografts may provide for 
long-lasting protec tion and perhaps even some degree of 
immunological tolerance. Unfortunately, it is completely 
unclear why there is such a divergent response to two 
foreign entities expressing the same foreign protein. Does 
this divergence relate to the microenvironmental 
conditions under which allograft versus microbiological 
antigens are presented to the immune system, or are 
other factors responsible? Th is is clearly an intriguing 
area of research, and high lights the importance of mTOR’s 
role in orchestrating complex immune responses.
Role of mTOR in B-cell and antigen-presenting cell 
development
Less information exists regarding the role of mTOR 
inhibitors on B cells. However, data from the mTOR 
hypomorph mouse (constitutive reduced, but not absent, 
mTOR levels) suggest that B-cell development may be 
even more aﬀ ected than T cells [33]. In these mice, B-cell 
development in the bone marrow is partially inhibited, 
which was reﬂ ected by decreased B-cell proliferation in 
response to antigenic stimulation and reduced antibody 
production capability. Interestingly, mice with B cells that 
overexpress mTOR because of a TSC1 deletion (TSC1 
normally inhibits mTOR, see Figure 1) also demonstrate 
similar defects in B-cell diﬀ erentiation and antibody 
production [34]. Another indication for an mTOR role 
comes from the fact that activated B cells, like T cells, use 
glycolysis as a primary source of energy [35]. Together, 
these early experimental indications suggest that mTOR 
is likely to have a signiﬁ cant impact on B-cell activation, 
diﬀ erentiation and function, but more in-depth studies 
are lacking to deﬁ ne the exact role of mTOR in B-cell-
mediated immunity.
Finally, the mTOR pathway is also important for the 
diﬀ erentiation and function of APCs. In particular, 
mTOR inhibition has a potent eﬀ ect on the maturation of 
dendritic cells (DCs). Diﬀ erentiation into conventional, 
CD8+ and plasmacytoid DCs appears to depend on 
mTOR. Indeed, mice with uninhibited mTOR activity 
(via PTEN deletion, see Figure  1) develop an abnormal 
highly expanded DC compartment [36], suggesting that 
mTOR plays a critical role in maintaining APC homeo-
stasis in vivo. Moreover, rapamycin treatment has a pro-
found eﬀ ect on APC function, in that co-stimulatory 
molecule expression is decreased, leading to an inhibited 
ability for APC to stimulate T-cell activation [37,38]. 
Rapa mycin-treated DCs are even known to induce 
tolerance in animal models [39,40], possibly through 
their ability to promote the development of Treg cells 
[41]. In fact, researchers that are expanding Treg cells for 
the purpose of cell therapy often use rapamycin to pro-
duce a more stable Treg phenotype [42]. One should 
mention, however, that rapamycin has seemingly oppos-
ing eﬀ ects on the early development of immune res-
ponses involving plasmacytoid DCs versus other DCs. 
While plasmacytoid DCs activated via toll-like receptors 
depend on mTOR to elicit type 1 interferon-based expres-
sion responses, lipopolysaccharide activation of mono-
cytes and DCs leads to inhibition of a proinﬂ ammatory 
gene expression pattern through the mTOR pathway [43]; 
mTOR inhibition could thus aﬀ ect responses to bacterial 
challenges, especially in immunosuppressed transplant 
recipients. mTOR therefore has important eﬀ ects on 
APC homeostasis and development that require a great 
deal more research to be fully understood. Nonetheless, 
mTOR clearly has yet another key function in the 
development of immune responses.
Conclusion
What was once thought to be a simple explanation (anti-
proliferative eﬀ ect) for how mTOR inhibitors reduce the 
immune reaction to organ allografts is now developing 
into a very complex explanation. One should also state 
that while several nonimmunological mechanistic expla-
na tions for the anti-tumour eﬀ ects of mTOR inhibitors 
have been described [44], promotion of immune res-
ponses to cancer is unexpectedly coming more into 
focus. Th e most recent data suggest that mTOR acts as a 
central node for coordinating activities of the most 
important cells (T cells, B cells and APCs) forming the 
immune response to various challenges. Interestingly, 
some of these eﬀ ects inhibit an immune response, and 
other eﬀ ects actually promote immunity; the setting of 
the antigenic challenge appears to be crucial, since energy 
availability, signalling cues and cell activation all converge 
to at least some degree upon mTOR.
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What does this mean for transplant patients in terms of 
allograft protection (immunosuppression), viral or 
bacterial infection and post-transplant malignancy? 
Although there are no simple answers to this question, 
more light is being shed on the topic with intensive 
ongoing research. In terms of protecting allografts from 
rejection, mTOR inhibitors are attractive from the 
theoretical perspective that they might be optimal for 
maintaining a state of donor-speciﬁ c regulation through 
promotion of tolerogenic DCs and Treg cells. Although 
mTOR inhibitors alone do not appear to produce 
tolerance in transplant recipients [45,46], perhaps 
strategic use of these drugs in combination with novel 
induction therapies or cell therapy [47,48] could yield 
better results. Regarding infectious complications asso-
ciated with immunosuppression in organ transplantation, 
there is already early evidence that mTOR inhibitors 
might reduce the problem of some viral infections, 
including cytomegalovirus, human herpesvirus 8 and BK 
virus [49-54]. In turn, if viral infections can be decreased, 
mTOR inhibitors could have an indirect impact on the 
development of post-transplant malig nan cies. In addition, 
promotion of memory CD8+ T-cell responses against 
tumour cells could also lessen the problem of cancer in 
transplant recipients.
To conclude, although early evidence suggests that 
mTOR inhibitors have the potential to promote an 
immune response against an infectious microorganism 
or tumour entity, and can paradoxically function to 
inhibit immunity against an organ allograft, further 
research is needed to untangle the operative mechanisms 
and to ultimately explore the full potential of mTOR 
inhibitors in the setting of organ transplantation.
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